Enveric Biosciences

06/05/2026

The recent U.S. executive order focused on accelerating research and regulatory review of psychedelic therapies has sparked renewed discussion across the neuropsychiatric sector.

Beyond potential regulatory efficiencies, the order highlights growing recognition that mental health innovation remains a national priority.

For researchers, investors, and patients alike, the conversation is no longer whether new approaches are needed.

It's how quickly they can be developed.

Read the Executive Order:
https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered: Section 1. Purpose and

06/03/2026

Despite decades of innovation, approximately one-third of patients with depression do not respond adequately to existing treatments.

Treatment-resistant depression remains one of the largest unmet needs in medicine and a major driver of innovation across neuroscience.

Researchers continue exploring novel mechanisms that may address the underlying biology of these disorders rather than simply managing symptoms.

Source:
https://www.labiotech.eu/in-depth/new-antidepressants-treatment-resistant-depression/

Take a look at how new antidepressants can more effectively tackle treatment resistant depression compared to more traditional treatments.

06/02/2026

Advancing a novel therapeutic from discovery to the clinic requires a series of critical development milestones.

Enveric has initiated IND-enabling genotoxicity studies for its lead neuroplastogen candidate, EB-003, an important step in the regulatory pathway toward first-in-human clinical trials.

Genotoxicity studies are designed to evaluate whether a compound has the potential to damage genetic material and are a key component of the safety package required for an Investigational New Drug (IND) application.

As Enveric continues to advance EB-003, each completed study contributes to building the data package needed to support future clinical development.
Read more:

https://www.businesswire.com/news/home/20260602535123/en/Enveric-Biosciences-Initiates-Investigational-New-Drug-IND-enabling-Genotoxicity-Studies-of-Lead-Neuroplastogen-Candidate-EB-003

$ENVB

06/02/2026

As interest in psychedelic-inspired therapies continues to grow, a new question is emerging:

Can these treatments scale?

Many first-generation psychedelic therapies require extensive monitoring, multiple healthcare providers, and specialized clinic infrastructure.

As the field matures, scalability may become just as important as efficacy. This is one reason why growing attention is being paid to orally administered neuroplastogens designed to fit more naturally within existing healthcare systems.

Read more:
https://www.reuters.com/legal/litigation/trumps-psychedelic-drug-order-boosts-investor-interest-with-promise-faster-2026-05-18/

05/28/2026

One of the most important scientific developments in psychedelic-inspired medicine may not be a clinical trial.

A recently published Nature paper suggests that different signalling pathways downstream of the 5-HT2A receptor may drive distinct biological effects, including neuroplasticity and hallucination.

For years, researchers have sought to understand whether the therapeutic benefits associated with psychedelics can be separated from the hallucinogenic experience.
The findings are helping shape the next generation of neuroplastogenic drug development and may influence how future compounds are designed.

Read the research:
https://www.nature.com/articles/s41586-025-10061-7

05/21/2026

A new Reuters feature examines how the recent U.S. executive order focused on accelerating psychedelic drug development is driving renewed investor attention across the neuropsychiatric treatment landscape.

The article highlights growing interest in scalable next-generation neuroplastogens, including Enveric’s lead candidate EB-003, as the industry moves toward therapies designed to deliver neuroplastic benefits with reduced monitoring requirements and broader clinical practicality.

“Scalability and commercial practicality should become increasingly important in differentiating innovative therapies.”
— Joseph Tucker, CEO, Enveric Biosciences

Read the Reuters feature: https://www.reuters.com/legal/litigation/trumps-psychedelic-drug-order-boosts-investor-interest-with-promise-faster-2026-05-18/

$ENVB

05/20/2026

The conversation around depression treatment is evolving and so is the science behind it.

A new feature from Labiotech explores the growing momentum behind next-generation antidepressants, including emerging neuroplastogens designed to promote neuroplasticity while improving scalability and accessibility across healthcare systems.

The article highlights Enveric’s lead candidate EB-003 and the broader shift toward non-hallucinogenic neuroplastogenic therapies for conditions including treatment-resistant depression, PTSD and anxiety.

“We think investors and pharma companies will increasingly focus on differentiation, scalability, and overall healthcare system fit, not just whether a compound is psychedelic.”
— Joseph Tucker, CEO, Enveric Biosciences

Read the full feature: https://www.labiotech.eu/in-depth/new-antidepressants-treatment-resistant-depression/

$ENVB

05/20/2026

Enveric today announced positive preclinical phototoxicity results for EB-003, with analysis showing no photoreactive potential.

This marks another important preclinical safety assessment milestone as Enveric continues to de-risk EB-003, its lead neuroplastogen candidate designed to promote neuroplasticity without hallucinogenic effects for neuropsychiatric disorders including depression, anxiety and PTSD.

Read the full release: https://www.businesswire.com/news/home/20260519940575/en/Enveric-Biosciences-Reports-Positive-Preclinical-Results-from-Phototoxicity-Analysis-for-Lead-Neuroplastogen-Candidate-EB-003

$ENVB

05/19/2026

Enveric's EB-003 has the potential to be a fast-acting, durable neuroplastogen utilizing a differentiated dual-pathway mechanism that activates therapeutic signaling downstream of the 5-HT2A receptor, potentially separating therapeutic benefits from hallucinations and reducing treatment burden for neuropsychiatric disorders. Learn more: https://bit.ly/3pbHq9W

05/15/2026

Enveric today reported financial results for the first quarter ended March 31, 2026, and provided a comprehensive business update. See it here: https://bit.ly/4uQd0dg